首页
400-620-6333
小分子和化合物库
选项
-
硫酸奎宁荧光标准物质分子式: C40H48N4O4.H2SO4.2H2O 分子量: 782.95IUPAC Name: (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid;dihydrateSMILES: COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.O.O.OS(=O)(=O)OInChIKey: ZHNFLHYOFXQIOW-LPYZJUEESA-NInChI: See more
-
Amoxicillin SodiumCAS号: 34642-77-8分子式: C16H18N3O5S.Na 分子量: 387.39IUPAC Name: sodium;(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylateSMILES: CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)[O-])C.[Na+]InChIKey: BYHDFCISJXIVBV-YWUHCJSESA-MInChI: 1S/C16H19N3O5S.Na/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);/q;+1/p-1/t9-,10-,11+,14-;/m1./s1
-
63 反式-2-（3-氯-5-氟苯基）环丙烷-1-羧酸CAS号: 2227899-38-7 Compound CID : 155905706分子式: C10H8ClFO2 分子量: 214.62IUPAC Name: (1R,2R)-2-(3-chloro-5-fluorophenyl)cyclopropane-1-carboxylic acidSMILES: C1C(C1C(=O)O)C2=CC(=CC(=C2)Cl)FInChIKey: RNQXIRVGVKKDHI-DTWKUNHWSA-NInChI: 1S/C10H8ClFO2/c11-6-1-5(2-7(12)3-6)8-4-9(8)10(13)14/h1-3,8-9H,4H2,(H,13,14)/t8-,9+/m0/s1
-
羧乙基锗倍半氧化物(GE 132)分子式: C6H10Ge2O7 分子量: 339.42IUPAC Name: 3-[[2-carboxyethyl(oxo)germyl]oxy-oxogermyl]propanoic acidSMILES: C(C[Ge](=O)O[Ge](=O)CCC(=O)O)C(=O)OInChIKey: XEABSBMNTNXEJM-UHFFFAOYSA-NInChI: 1S/C6H10Ge2O7/c9-5(10)1-3-7(13)15-8(14)4-2-6(11)12/h1-4H2,(H,9,10)(H,11,12)
-
四螨嗪CAS号: 74115-24-5 EC号: 277-728-2分子式: C14H8Cl2N4 分子量: 303.15IUPAC Name: 3,6-bis(2-chlorophenyl)-1,2,4,5-tetrazineSMILES: C1=CC=C(C(=C1)C2=NN=C(N=N2)C3=CC=CC=C3Cl)ClInChIKey: UXADOQPNKNTIHB-UHFFFAOYSA-NInChI: 1S/C14H8Cl2N4/c15-11-7-3-1-5-9(11)13-17-19-14(20-18-13)10-6-2-4-8-12(10)16/h1-8H
-
羧苄青霉素 二钠盐分子式: C17H16N2O6SNa2 分子量: 422.36IUPAC Name: disodium;(2S,5R,6R)-6-[(2-carboxylato-2-phenylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylateSMILES: CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)[O-])C(=O)[O-])C.[Na+].[Na+]InChIKey: RTYJTGSCYUUYAL-YCAHSCEMSA-LInChI: 1S/C17H18N2O6S.2Na/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8;;/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25);;/q;2*+1/p-2/t9?,10-,11+,14-;;/m1../s1
-
Belantamab mafodotin (anti-BCMA)关联靶标: TNFRSF17
- 简短描述: Purity≥90% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgG1; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAF)
- 种属反应性: 人(Human), 食蟹猴(Cynomolgus monkey)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: MC-VC-PAB-MMAF
CAS号: 2050232-20-5SMILES: [Belantamab mafodotin] -
Lifastuzumab vedotin (anti-SLC34A2)关联靶标: SLC34A2
- 简短描述: Purity≥90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (MC-VC-PAB-MMAE)
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: MC-VC-PAB-MMAE
CAS号: 1401812-88-1 -
Lorvotuzumab mertansine (anti-NCAM1)关联靶标: NCAM1
- 简短描述: Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (SMCC-DM1)
- 种属反应性: 人(Human)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: SMCC-DM1
CAS号: 1008106-64-6 -
Lutikizumab (anti-IL1a&IL1b)
- 简短描述: Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human), 小鼠(Mouse), 食蟹猴(Cynomolgus monkey)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号: 1791411-57-8 -
Labetuzumab govitecan (anti-CEACAM5)关联靶标: CEACAM5
- 简短描述: Purity>90% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Conjugated (CL2A-SN-38)
- 种属反应性: 人(Human), 小鼠(Mouse), 食蟹猴(Cynomolgus monkey)
- 亚型: Human IgG1
- 宿主种属: 人(Human)
- 偶联: CL2A-SN-38
CAS号: 1469876-18-3 Compound CID : 91668184SMILES: See more -
Ozoralizumab (anti-TNF-alpha&HSA)
- 简短描述: Purity≥90% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
- 种属反应性: 人(Human)
- 宿主种属: 人(Human)
- 偶联: Unconjugated
CAS号: 1167985-17-2
